SK Biopharmaceuticals will expand support for Korean pharmaceutical and biotechnology companies seeking to establish a presence in the U.S. The company has opened a shared business and advisory platform called SK Life Science LinX, designed to help companies navigate regulatory, clinical, and commercial challenges. A total of 31 companies have been selected to participate in this initiative, which is now moving into full operation.
Located in the U.S., LinX provides office space, meeting facilities, and infrastructure for companies looking to develop relationships with potential U.S. partners. The initiative will focus on five critical areas: FDA regulatory pathways, company formation and taxation, intellectual property and patent strategy, clinical development and technology transfer, and business development.
Support will be tailored to each company’s requirements, with one-on-one advisory sessions connecting them to relevant U.S. institutions and industry experts. The program aims to create opportunities for participants to connect with U.S. companies and includes training in technology presentations and business development.
Source: drug-dev.com · Image: National Parliament Business Advisory Committee meeting April 24 2016 by Press Information Department, Public domain, via Wikimedia Commons
Get started today with Solo access →
